Published in PLoS One on September 17, 2014
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol (2015) 1.02
Formation of stable small cell number three-dimensional ovarian cancer spheroids using hanging drop arrays for preclinical drug sensitivity assays. Gynecol Oncol (2015) 0.82
YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells. Oncogene (2015) 0.81
FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer. Oncotarget (2015) 0.80
DNA methylation changes in epithelial ovarian cancer histotypes. Genomics (2015) 0.80
Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals. Sci Rep (2015) 0.79
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer Medicine. Yonsei Med J (2015) 0.79
Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells. Oncotarget (2016) 0.78
miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. Mol Cancer (2015) 0.78
Selective targeting of Cyclin E1 amplified high grade serous ovarian cancer by cyclin-dependent kinase 2 and AKT inhibition. Clin Cancer Res (2016) 0.78
The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells. Oncotarget (2016) 0.77
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells. Sci Rep (2017) 0.76
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators. J Ovarian Res (2016) 0.76
Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer. Mol Pharm (2016) 0.76
Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. Br J Cancer (2016) 0.76
Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget (2016) 0.76
MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun (2015) 0.76
Identification of epithelial ovarian tumor-specific aptamers. Nucleic Acid Ther (2015) 0.76
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. Genome Med (2016) 0.76
Active FOXO1 Is a Key Determinant of Isoform-Specific Progesterone Receptor Transactivation and Senescence Programming. Mol Cancer Res (2015) 0.76
Effect of IL-6 and IL-8 on the expression of the complement activation inhibitors MAC-inhibitory protein and decay-accelerating factor in ovarian cancer A2780 cells. Oncol Lett (2016) 0.75
Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res (2016) 0.75
Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells. Cancer Lett (2015) 0.75
Protein tyrosine phosphatase PTPN3 promotes drug resistance and stem cell-like characteristics in ovarian cancer. Sci Rep (2016) 0.75
Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget (2017) 0.75
Ovarian cancer stem cells: still an elusive entity? Mol Cancer (2017) 0.75
The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro. Int J Oncol (2016) 0.75
Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun (2016) 0.75
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. Cell Cycle (2017) 0.75
Genome-wide DNA copy number analysis in clonally expanded human ovarian cancer cells with distinct invasive/migratory capacities. Oncotarget (2017) 0.75
Altered glutamine metabolism in platinum resistant ovarian cancer. Oncotarget (2016) 0.75
Prognostic and therapeutic value of disruptor of telomeric silencing-1-like (DOT1L) expression in patients with ovarian cancer. J Hematol Oncol (2017) 0.75
Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol (2016) 0.75
Correction: Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One (2015) 0.75
Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75
VEPH1 expression decreases vascularisation in ovarian cancer xenografts and inhibits VEGFA and IL8 expression through inhibition of AKT activation. Br J Cancer (2017) 0.75
Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model. Oncotarget (2017) 0.75
A comprehensively characterized cell line panel highly representative of clinical ovarian high-grade serous carcinomas. Oncotarget (2016) 0.75
Integrated genomic analyses of ovarian carcinoma. Nature (2011) 47.72
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Cancer genome landscapes. Science (2013) 25.33
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst (1977) 6.91
A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol (2009) 6.25
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol (2010) 5.23
CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer (2011) 4.54
Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun (2013) 4.35
Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res (2005) 3.79
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle (2009) 3.60
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res (1983) 2.90
The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol (2012) 2.59
Comparative properties of five human ovarian adenocarcinoma cell lines. Cancer Res (1985) 2.50
Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov (2011) 2.49
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics (2011) 2.43
Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40
Molecular profiling of platinum resistant ovarian cancer. Int J Cancer (2006) 2.37
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol (2005) 2.37
Overview of the matrisome--an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol (2012) 2.26
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res (2011) 2.03
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One (2010) 1.97
Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim (2000) 1.91
The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat (2012) 1.77
Mutation discovery by targeted genomic enrichment of multiplexed barcoded samples. Nat Methods (2010) 1.77
Type-specific cell line models for type-specific ovarian cancer research. PLoS One (2013) 1.73
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol (2012) 1.71
Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res (2008) 1.61
Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem (2011) 1.60
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br J Cancer (1989) 1.56
Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient. Int J Cancer (1987) 1.47
The changing view of high-grade serous ovarian cancer. Cancer Res (2012) 1.46
The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer Treat Rev (2013) 1.43
Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin Oncol (1984) 1.41
Two multiplex assays that simultaneously identify 22 possible mutation sites in the KRAS, BRAF, NRAS and PIK3CA genes. PLoS One (2010) 1.41
Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res (2007) 1.40
Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol (2014) 1.40
Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Cancer Res (1991) 1.39
Multiplexed array-based and in-solution genomic enrichment for flexible and cost-effective targeted next-generation sequencing. Nat Protoc (2011) 1.36
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia (2007) 1.29
Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst (1984) 1.24
Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer (1993) 1.24
Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol (2010) 1.22
The role of targeted therapy in ovarian cancer. Eur J Cancer (2011) 1.20
CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis (2012) 1.18
Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. Breast Cancer Res Treat (2013) 1.08
FilGAP, a Rho/Rho-associated protein kinase-regulated GTPase-activating protein for Rac, controls tumor cell migration. Mol Biol Cell (2012) 1.08
Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer (2006) 1.07
N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One (2013) 1.06
EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res (2011) 1.06
Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol (2009) 1.04
Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene (2012) 1.04
Genotypic and phenotypic characterization of side population of gastric cancer cell lines. Am J Pathol (2011) 1.03
Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer. Breast Cancer Res Treat (2013) 1.02
Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. Eur J Cancer (2013) 1.02
Cooperative anti-invasive effect of Cdc42/Rac1 activation and ROCK inhibition in SW620 colorectal cancer cells with elevated blebbing activity. PLoS One (2012) 1.02
Characterization of an ovarian carcinoma cell line. Cancer (1978) 0.99
cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res (1988) 0.99
Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene (2012) 0.95
Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations. Breast Cancer Res Treat (2009) 0.93
RhoB regulates cell migration through altered focal adhesion dynamics. Open Biol (2012) 0.93
Hyaluronic acid-paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts. Cancer Chemother Pharmacol (2010) 0.92
Mapping of chromosome 3p deletions in human epithelial ovarian tumors. Oncogene (1998) 0.92
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol (2011) 0.89
Notch3 induces epithelial-mesenchymal transition and attenuates carboplatin-induced apoptosis in ovarian cancer cells. Gynecol Oncol (2013) 0.86
Paradoxical increase in DNA cross-linking in a human ovarian carcinoma cell line resistant to cyanomorpholino doxorubicin. Cancer Res (1990) 0.85
Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors. Cancer Res (1983) 0.83
Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol Oncol (1988) 0.83
Effects of interferons on the expression of the proto-oncogene HER-2 in human ovarian carcinoma cells. Int J Cancer (1992) 0.83
Sorting and identification of side population cells in the human cervical cancer cell line HeLa. Cancer Cell Int (2014) 0.81
Characterisation of seven human ovarian tumour cell lines. Br J Cancer (1996) 0.77
First line therapy: have we made any improvement? Eur J Cancer (2011) 0.77
Differential hRad17 expression by histologic subtype of ovarian cancer. J Ovarian Res (2011) 0.77